Sanofi completes acquisition of biopharmaceutical company Blueprint for over $9 billion

On July 18th, Sanofi announced the completion of its acquisition of the American biopharmaceutical company Blueprint Medicines. The acquisition includes a rare immune disease drug Ayvakit/Ayvakyt (avapritinib), which has been approved in the United States and the European Union. According to the acquisition terms announced in June this year, Sanofi will pay $129 in cash per share, with an equity value of approximately $9.1 billion. (Jiemian)